(Q36055317)

11 August 2017

Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study (English)

1 reference

multicenter clinical trial

11 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

1 reference

G Freyer

1

1 reference

11 August 2017

B Tranchand

2

1 reference

11 August 2017

B Ligneau

3

1 reference

11 August 2017

C Ardiet

4

1 reference

11 August 2017

P J Souquet

5

1 reference

11 August 2017

I Court-Fortune

6

1 reference

11 August 2017

R Riou

7

1 reference

11 August 2017

P Rebattu

8

1 reference

11 August 2017

J P Boissel

9

1 reference

11 August 2017

V Trillet-Lenoir

10

1 reference

11 August 2017

P Girard

11

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

British Journal of Clinical Pharmacology

11 August 2017

1 reference

11 August 2017

50

1 reference

11 August 2017

4

1 reference

11 August 2017

315-324

1 reference

A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

Ifosfamide clinical pharmacokinetics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

Clinical pharmacokinetics of doxorubicin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

The importance of modeling interoccasion variability in population pharmacokinetic analyses

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

Limited sampling models for doxorubicin pharmacokinetics

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

Population pharmacokinetics of total and unbound etoposide.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014997

High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection

23 September 2018

1 reference

12 December 2020

Rapid gas chromatographic determination of ifosfamide in biological fluids

1 reference

12 December 2020

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

12 December 2020

Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma

1 reference

12 December 2020

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer

1 reference

12 December 2020

Limited disease small cell lung cancer: alternating combination of doxorubicin, etoposide, ifosfamide and hyperfractionated radiotherapy. Final results of a multicentric pilot study for the Groupe Lyonnias d'Oncologie Thoracique (GLOT)

1 reference

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

12 December 2020

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

12 December 2020

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

1 reference

12 December 2020

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

12 December 2020

Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy

1 reference

12 December 2020

10.1046/J.1365-2125.2000.00269.X

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

11012554

1 reference